FrancophonIA/ELRC3.0 huggingface dataset:
English: Examples include: - you have not injected your insulin or not injected enough, or if it has become less effective, for example through incorrect storage, - you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever, - you are taking or have taken certain other medicines (see section 2, "Other medicines and
Estonian: Näiteks: - te ei ole süstinud insuliini või olete süstinud seda liiga vähe või insuliini efektiivsus on vähenenud, nt vale säilitamise tõttu, - teie kehaline aktiivsus on tavalisest vähenenud, te olete stressis (emotsionaalne stress, ärevus),
English: EU/1/04/285/029 1 pen of 3 ml.
Estonian: EU/1/04/285/029 1 pen-süstel,3 ml
English: After injection, the site of injection should not be massaged.
Estonian: Süstekohta ei tohi pärast süsti masseerida.
English: However, insulin requirements may be reduced in the presence of renal impairment.
Estonian: Neerukahjustuse korral võib insuliinivajadus siiski väheneda.
English: Once in use, the vial may be stored for a maximum of 4 weeks in the outer carton below 25°C away from direct heat or direct light.
Estonian: Kasutusse võetud viaali võib hoida välispakendis maksimaalselt 4 nädalat temperatuuril kuni 25°C, otsese kuumuse või valguse eest kaitstult.
English: Please check section 6.4 of this SPC for instructions on how to store SoloStar.
Estonian: SoloStar'i säilitamisjuhiste kohta lugege palun selle ravimi omaduste kokkuvõtte lõiku 6.4.
English: Only needles that are compatible for use with SoloStar should be used.
Estonian: Kasutada tohib ainult SoloStar'ile sobivaid nõelu.
English: Always have available an alternative insulin delivery system for injection under the skin (see section 3 under “How to handle an infusion pump system” and “What to do if the pump system fails or when the pump is used incorrectly”).
Estonian: „Kuidas käsitseda infusioonipumpa?“ ja „Mida teha, kui infusioonipump ei tööta või seda on kasutatud valesti?“)
English: Store in a refrigerator (2°C - -8°C).
Estonian: Hoida külmkapis (2°C...8°C).
English: Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall.
Estonian: Apidra't manustatakse subkutaanselt kõhuseina, reide või deltalihase piirkonda või püsiinfusioonina kõhuseina.
English: Apidra SoloStar 100 units/ml in pre-filled pen is only suitable for subcutaneous injections.
Estonian: Apidra SoloStar 100 ühikut/ml eeltäidetud pen-süstlis sobib ainult subkutaanseks manustamiseks.
English: When insulin glulisine was injected subcutaneously into abdomen, deltoid and thigh, the concentration-time profiles were similar with a slightly faster absorption when administered in the abdomen compared to the thigh.
Estonian: Glulisiin-insuliini manustamisel subkutaanselt kõhu eesseina, deltalihase piirkonda ja reide olid kontsentratsiooni-aja profiilid sarnased.
English: 1 vial of 10ml.
Estonian: Süstelahus viaalis 1 viaal 10 ml
English: Cases of diabetic ketoacidosis have been reported when Apidra has been given in continuous subcutaneous insulin infusion in pump systems.
Estonian: Apidra manustamisel subkutaanse püsiinfusioonina infusioonipumbaga on teatatud diabeetilise ketoatsidoosi juhtudest.
English: METHOD OF ADMINISTRATION Use specific pens: see leaflet.
Estonian: Kasutada ettenähtud pen-süstlis: vt infoleht.
English: It must only be used if the solution is clear and colourless, not when cloudy or with visible particles.
Estonian: Lahust võib kasutada ainult siis, kui see on selge ja värvitu, mitte hägune või nähtavaid osakesi sisaldav.
English: Apidra 100 Units/ml solution for injection in a vial Cases of hyperglycaemia have been reported with Apidra when used with CSII (see section 4.4) that has led to Diabetic Ketoacidosis (DKA); most of the cases were related to handling errors or pump system failure.
Estonian: Apidra manustamisel subkutaanse püsiinfusioonina (vt lõik 4.4) on teatatud hüperglükeemia juhtudest, mis põhjustasid diabeetilist ketoatsidoosi.
English: Continuous subcutaneous insulin infusion
Estonian: Insuliini subkutaanne püsiinfusioon
English: A dose should not be selected and/or the injection button should not be pressed without a needle attached.
Estonian: Kui nõel ei ole kinnitatud, ärge valige annust ja (või) suruge süstimisnuppu.
English: Each cartridge contains 3 ml of solution for injection, equivalent to 300 Units.
Estonian: Iga kolbampull sisaldab 3 ml süstelahust, mis vastab 300 Ühikule.
English: Lipodystrophy
Estonian: Metakresool
English: A phase I study in patients with type 1 diabetes mellitus assessed the glucose lowering profiles of insulin glulisine and regular human insulin administered subcutaneously at a dose of 0.15 Units/kg, at different times in relation to a 15-minute standard meal.
Estonian: I faasi uuringus hinnati glulisiin-insuliini ja lühitoimelise iniminsuliini vere suhkrusisaldust langetava toime profiili, manustades 1. tüüpi suhkurtõvega patsientidele subkutaanselt 0,15 Ühikut/kg.
English: It must only be used if the solution is clear, colourless, with no solid particles visible.
Estonian: Kasutage seda ainult juhul kui lahus on selge, värvitu ja ilma nähtavate osakesteta.
English: EU/1/04/285/001 1 vial of 10ml EU/1/04/285/002 2 vials of 10ml.
Estonian: EU/1/04/285/001 1 viaal, 10 ml
English: Treatment of adults, adolescents and children 6 years or older, with diabetes mellitus, where treatment with insulin is required.
Estonian: Insuliinravi vajava suhkurtõve ravi täiskasvanutel, noorukitel ja 6-aastastel või vanematel lastel.
English: Before first use, the pen must be stored at room temperature for 1 to 2 hours.
Estonian: Enne esmast kasutamist hoidke pen-süstlit 1...2 tundi toatemperatuuril.
English: Apidra 100 Units/ml solution for injection in a cartridge 3 ml solution in a cartridge (type I colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
Estonian: 3 ml lahust kolbampullis (I tüüpi värvitu klaas) kolviga (elastomeerne broombutüülkumm) ning ääristava pealdisega (alumiinium) ja korgiga (elastomeerne broombutüülkumm).
English: Apidra 100 Units/ml solution for injection in a cartridge Pens to be used with Apidra 100 units/ml solution for injection in a cartridge Apidra 100 units/ml in cartridges is only suitable for subcutaneous injections from a reusable pen.
Estonian: Pen-süstlid, mida tohib kasutada Apidra 100 ühikut/ml süstelahuse kolbampullidega Apidra 100 ühikut/ml kolbampullis sobib ainult subkutaanseks manustamiseks korduvkasutatava pen-süstliga.
English: Keep the pen protected from light.
Estonian: Hoida pen-süstel valguse eest kaitstult.
English: Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injection to the next.
Estonian: Süste- ja infusioonikohti tuleb süstepiirkonna piires (kõht, reis, deltalihas) iga süstekorraga roteerivalt vahetada.
English: Apidra 100 Units/ml solution for injection in a vial Intravenous use
Estonian: Apidra 100 Ühikut/ml süstelahus viaalis Intravenoosne
English: Apidra 100 Units/ml solution for injection in a vial Each vial contains 10 ml of solution for injection, equivalent to 1000 Units.
Estonian: Iga ml sisaldab 100 Ühikut glulisiin-insuliini (vastab 3,49 mg) Iga viaal sisaldab 10 ml süstelahust, mis vastab 1000 Ühikule.
English: Vistor hf.
Estonian: Süstelahus viaalis.
English: Packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.
Estonian: Pakendis on 1, 3, 4, 5, 6, 8, 9 või 10 kolbampulli.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (cartridge)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED VÄLISPAKEND (kolbampull)
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL (cartridge)
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens are available.
Estonian: Pakendis on 1, 3, 4, 5, 6, 8, 9 või 10 pen-süstlit.
English: 5 pens of 3 ml.
Estonian: 1 pen-süstel, 3 ml
English: Attach the needle
Estonian: Kinnitage nõel
English: Talk to your doctor, pharmacist or nurse before using Apidra.
Estonian: Enne Apidra kasutamist pidage nõu oma arsti, apteekri või meditsiiniõega.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 Units insulin glulisine (equivalent to 3.49 mg).
Estonian: Iga milliliiter lahust sisaldab 100 Ühikut glulisiin-insuliini (vastab 3,49 mg).
English: Insulin reservoir
Estonian: Kontrollige insuliini
English: Consult your insulin pen instruction booklet for further details.
Estonian: Täiendava informatsiooni saamiseks vaadake insuliini pen-süstli kasutamisjuhendit.
English: EU/1/04/285/008 5 cartridges of 3ml.
Estonian: EU/1/04/285/005 1 kolbampull, 3 ml
English: Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen 3 ml solution in a cartridge (colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
Estonian: 3 ml lahust kolbampullis (värvitu klaas) kolviga (elastomeerne broombutüülkumm) ning ääristava pealdisega (alumiinium) ja korgiga (elastomeerne broombutüülkumm).
English: Speak to your doctor if you need to inject your insulin by another method.
Estonian: Kui peate süstima insuliini muul viisil, pidage nõu oma arstiga.
English: MARKETING AUTHORISATION HOLDER Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Germany.
Estonian: Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Saksamaa.
English: MedDRA
Estonian: Hooldus
English: SoloStar.
Estonian: Neerukahjustus
English: Look at the vial before you use it. Only use it if the solution is clear, colourless and has no visible particles in it.
Estonian: Kasutage viaali ainult siis, kui selles sisalduv lahus on selge, värvitu ja ei sisalda nähtavaid osakesi.
English: Subcutaneous use
Estonian: Subkutaanne kasutamine
English: - sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma), - thyroid hormones (used to treat thyroid gland disorders), - protease inhibitors (used to treat HIV), - atypical antipsychotic medicines (such as olanzapine and clozapine).
Estonian: − sümpatomimeetilised ravimid (nt epinefriin (adrenaliin) või salbutamool, terbutaliin, mida kasutatakse astma raviks),
English: Local hypersensitivity reactions (redness, swelling and itching at the injection site) may occur during treatment with insulin.
Estonian: Insuliinravi ajal võivad esineda kohalikud ülitundlikkusreaktsioonid (punetus, turse ja sügelus süstekohal).
English: Keep the cartridge inserted in the pen protected from light.
Estonian: Kolbampulli peab hoidma pen-süstlis kaitstuna valguse eest.
English: NAME OF THE MEDICINAL PRODUCT Apidra 100 Units/ml solution for injection in a vial Apidra 100 Units/ml solution for injection in a cartridge Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen
Estonian: Pakendi infoleht: teave kasutajale Apidra 100 Ühikut/ml süstelahus kolbampullis
English: OTHER SPECIAL WARNING(S), IF NECESSARY Use only clear and colourless solutions.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL)
English: Apidra 100 Units/ml solution for injection in a vial Insulin glulisine
Estonian: Apidra 100 Ühikut/ml, süstelahus viaalis Insulinum glulisinum
English: Marketing Authorisation Holder: Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Germany
Estonian: Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main Saksamaa
English: Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen Insulin glulisine
Estonian: Apidra SoloStar 100 Ühikut/ml süstelahus pen-süstlis Insulinum glulisinum s.c.
English: In a 26-week phase III clinical study comparing insulin glulisine with insulin lispro both injected subcutaneously shortly (0-15 minutes) before a meal in patients with type 1 diabetes mellitus using insulin glargine as basal insulin, insulin glulisine was comparable to insulin lispro for glycaemic control as reflected by changes in glycated haemoglobin (expressed as HbA1c equivalent) from baseline to endpoint.
Estonian: 26-nädalases III faasi kliinilises uuringus võrreldi 1. tüüpi diabeediga patsientidel subkutaanselt vahetult enne sööki (0…15 minutit) manustatud glulisiin-insuliini ja lispro-insuliini, kasutades glargiin-insuliini basaalinsuliinina.
English: HYPERGLYCAEMIA (high blood sugar levels)
Estonian: − teil on hüperglükeemia (veresuhkru kõrge tase).
English: Apidra 100 Units/ml solution for injection in a cartridge Insulin glulisine
Estonian: Apidra 100 Ühikut/ml süstelahus kolbampullis Insulinum glulisinum
English: Apidra 100 Units/ml solution for injection in a vial
Estonian: Apidra 100 Ühikut/ml süstelahus viaalis
English: Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen.
Estonian: Apidra SoloStar 100 Ühikut/ml, süstelahus pen-süstlis.
English: Needle
Estonian: Rasedus
English: Apidra 100 Units/ml solution for injection in a cartridge Apidra 100 Units/ml in cartridges is only suitable for subcutaneous injections from a reusable pen.
Estonian: Apidra 100 ühikut/ml kolbampullis sobib ainult subkutaanseks manustamiseks korduvkasutatava pen-süstliga.
English: Step 5 Inject the dose
Estonian: 5. samm Süstige annus
English: 4 vials of 10ml.
Estonian: ETIKETT (10 ml viaal)
English: 1 cartridge of 3ml.
Estonian: Süstelahus kolbampullis 1 kolbampull, 3 ml
English: Injection button
Estonian: Hüpoglükeemia
English: Subcutaneous or intravenous use
Estonian: Kõlblikkusaeg intravenoossel kasutamisel
English: EU/1/04/285/005 1 cartridge of 3ml EU/1/04/285/006 3 cartridges of 3ml.
Estonian: EU/1/04/285/030 3 pen-süstlit, igas 3 ml EU/1/04/285/031 4 pen-süstlit, igas 3 ml EU/1/04/285/032 5 pen-süstlit, igas 3 ml EU/1/04/285/033 6 pen-süstlit, igas 3 ml EU/1/04/285/034 8 pen-süstlit, igas 3 ml EU/1/04/285/035 9 pen-süstlit, igas 3 ml EU/1/04/285/036 10 pen-süstlit, igas 3 ml
English: MA (EU) number (Invented) name Strength Pharmaceutical Form
Estonian: Manustamistee Sisepakendi iseloomustus Pakendi suurus
English: Immediate Packaging
Estonian: Tugevus Ravimvorm
English: The full EPAR for Tenofovir disoproxil Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Tenofovir disoproxil Zentiva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Tenofovir disoproxil Zentiva does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Estonian: Tenofovir disoproxil Zentiva ei ravi HIV-nakkust ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste tekkimist edasi lükata.
English: What measures are being taken to ensure the safe and effective use of Tenofovir disoproxil Zentiva?
Estonian: Mis meetmed võetakse, et tagada ravimi Tenofovir disoproxil Zentiva ohutu ja efektiivne kasutamine?
English: The company that markets Tenofovir disoproxil Zentiva will ensure that all doctors who are expected to prescribe or use the medicine are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
Estonian: Ravimi Tenofovir disoproxil Zentiva tootja tagab, et kõikidele ravimit Tenofovir disoproxil Zentiva määravatele või kasutavatele arstidele antakse teabematerjalid, mis sisaldavad olulist ohutusteavet, eelkõige neerutalitluse ja luudega seotud riskide ja ettevaatusmeetmete kohta.
English: Tenofovir disoproxil Zentiva stops the virus making DNA and prevents it from multiplying and spreading.
Estonian: Tenofovir disoproxil Zentiva peatab viiruse DNA moodustumise ning takistab viiruse paljunemist ja levikut.
English: In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Estonian: HIV-nakkuse korral blokeerib see pöördtranskriptaasi, mis on HIV-i tekitatav ensüüm, mis võimaldab viirusel rakke nakatada ja rakkudes paljuneda.
English: Tenofovir disoproxil Zentiva is available as tablets (245 mg) to be taken by mouth.
Estonian: Ravimit Tenofovir disoproxil Zentiva turustatakse suukaudsete tablettidena (245 mg).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tenofovir disoproxil Zentiva has been shown to have comparable quality and to be bioequivalent to Viread.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Tenofovir disoproxil Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Viread.
English: For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Tenofovir disoproxil Zentiva once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus's response to antiviral medicines.
Estonian: Kui patsient on HIV-nakkuse vastaseid ravimeid varem kasutanud, võib arst määrata ravimiga Tenofovir disoproxil Zentiva toimuva ravi üksnes arvestades patsiendi varem kasutatud viiruseravimeid ning viiruse ravimitele reageerimise tõenäosust.
English: The Committee recommended that Tenofovir disoproxil Zentiva be approved for use in the EU.
Estonian: Komitee soovitas ravimi Tenofovir disoproxil Zentiva kasutamise Euroopa Liidus heaks kiita.
English: Tenofovir disoproxil Zentiva is also used to treat chronic (long-term) hepatitis B virus infection in adults and adolescents aged 12 years and above with liver damage whose liver is still able to work (compensated liver disease).
Estonian: Ravimit Tenofovir disoproxil Zentiva kasutatakse ka kroonilise (pikaajalise) B-hepatiidi viiruse nakkuse raviks maksakahjustusega täiskasvanutel ja vähemalt 12-aastastel noorukitel, kelle maksatalitlus on veel korras (kompenseeritud maksahaigus).
English: This is a summary of the European public assessment report (EPAR) for Tenofovir disoproxil Zentiva.
Estonian: See on ravimi Tenofovir disoproxil Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tenofovir disoproxil Zentiva have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Tenofovir disoproxil Zentiva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Because Tenofovir disoproxil Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Tenofovir disoproxil Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Tenofovir disoproxil Zentiva tenofovir disoproxil
Estonian: Tenofovir disoproxil Zentiva tenofoviirdisoproksiil
English: Tenofovir disoproxil Zentiva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection or chronic hepatitis B.
Estonian: Tenofovir disoproxil Zentiva on retseptiravim ja ravi peab alustama HIV-nakkuse või kroonilise Bhepatiidi ravis kogenud arst.
English: What is Tenofovir disoproxil Zentiva and what is it used for?
Estonian: Mis on Tenofovir disoproxil Zentiva ja milleks seda kasutatakse?
English: For more information on how the medicine is taken including doses for adults and adolescents, see the summary of product characteristics (also part of the EPAR).
Estonian: Ravimi kasutamise, sealhulgas täiskasvanute ja noorukite annuste teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: In adults, it can also be used for those patients with liver damage whose liver does not work properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B).
Estonian: Ravimit Tenofovir disoproxil Zentiva tohib kasutada maksakahjustusega täiskasvanud patsientidel, kelle maksatalitlus ei ole korras (dekompenseeritud maksahaigus), ja patsientidel, kellele ravi lamivudiiniga (samuti B-hepatiidi ravim) ei mõju.
English: Tenofovir disoproxil Zentiva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Koos teiste viiruseravimitega manustatav Tenofovir disoproxil Zentiva vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: The dose may need to be reduced or the medicine given less often in patients who have moderately or severely reduced kidney function.
Estonian: Mõõduka või raske neeruhäirega patsientidel võib olla vaja annust vähendada või võtta ravimit harvem.
English: Tenofovir disoproxil Zentiva is an antiviral medicine used to treat patients aged 12 years and above infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Tenofovir disoproxil Zentiva on viiruseravim, mis on näidustatud omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava 1. tüüpi inimese immuunpuudulikkuse viiruse (HIV-1) nakkuse raviks vähemalt 12-aastastel patsientidel.
English: In adolescents (from 12 to 18 years of age) its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Estonian: Ravimit Tenofovir disoproxil Zentiva üksnes nendel noorukitel (12-18 a), keda ei saa ravida muude esmavaliku nukleotiidsete pöördtranskriptaasi inhibiitoritega (NRTI).
English: For practical information about using Tenofovir disoproxil Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Tenofovir disoproxil Zentiva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Tenofovir disoproxil Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Tenofovir disoproxil Zentiva toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Tenofovir disoproxil Zentiva
Estonian: Muu teave ravimi Tenofovir disoproxil Zentiva kohta
English: Tenofovir disoproxil Zentiva is used in combination with other HIV medicines.
Estonian: Ravimit Tenofovir disoproxil Zentiva kasutatakse koos muude HIVravimitega.
English: It is not intended to provide practical advice on how to use Tenofovir disoproxil Zentiva.
Estonian: Hindamisaruandes ei anta ravimi Tenofovir disoproxil Zentiva kasutamise praktilisi nõuandeid.
English: Because Tenofovir disoproxil Zentiva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Viread.
Estonian: Et Tenofovir disoproxil Zentiva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi Tenofovir disoproxil Zentiva bioekvivalentsust võrdlusravimiga Viread.
English: Tenofovir also interferes with the action of an enzyme produced by the hepatitis B virus called ‘DNA polymerase', which is involved in the formation of viral DNA.
Estonian: Lisaks häirib tenofoviir B-hepatiidi viiruse tekitatava ja viiruse DNA moodustumises osaleva ensüümi DNA-polümeraasi toimet.
English: Tenofovir disoproxil Zentiva contains the active substance tenofovir disoproxil.
Estonian: Tenofovir disoproxil Zentiva sisaldab toimeainena tenofoviirdisoproksiil.
English: The active substance in Tenofovir disoproxil Zentiva, tenofovir disoproxil, is a ‘prodrug' that is converted into tenofovir in the body.
Estonian: Ravimi Tenofovir disoproxil Zentiva toimeaine tenofoviirdisoproksiil on eelravim, mis muundub organismis tenofoviiriks.